NutriBand (NTRB) Gross Margin (2018 - 2026)

NutriBand (NTRB) posted Gross Margin of 45.41% for Q2 2026, up 104.58% sequentially from 22.2% in Q1 2026, and up 765.0% YoY from 5.25% in Q2 2025.

NutriBand (NTRB) Gross Margin (2018 - 2026) Analysis & Trends

NutriBand has reported Gross Margin for 9 years, with the latest figure at 45.41% in Q2 2026.

Quarterly Gross Margin rose 765.0% year-over-year to 45.41% in Q2 2026, while the trailing twelve-month figure through Apr 2026 was 28.35% (down 627.0% YoY) and the FY2026 annual result came in at 27.81%, down 694.0% from the prior year.
Gross Margin rose to 45.41% in Q2 2026 per NTRB's latest filing, from 22.2% in the prior quarter.
Over five years, Gross Margin peaked at 46.61% in Q2 2023 and troughed at 19.8% in Q4 2025.
A 5-year average of 35.21% and a median of 37.45% in 2023 frame the typical range for Gross Margin.
The sharpest annual moves came in 2022 and 2024: Gross Margin surged 8458 bps in 2022, then sank 2275 bps in 2024.
Over 5 years, Gross Margin stood at 43.48% in 2022, then declined by 15 bps to 37.14% in 2023, then fell by 20 bps to 29.58% in 2024, then slumped by 33 bps to 19.8% in 2025, then jumped by 129 bps to 45.41% in 2026.
According to Business Quant data, Gross Margin over the past three periods registered 45.41%, 22.2%, and 19.8% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	NutriBand	46.38 Mn	42.37 Mn	196,801.00	45.41%

Download Data